User Agreement

Important Information – Please Read

By accessing and using this document, you are agreeing to the following terms and conditions and all applicable laws.

These documents provide information on the results of certain drug studies initiated on or after October 15, 2002 sponsored or conducted by URL Pharma or its subsidiaries or affiliates. The nature and purpose of this document is to comply with certain applicable laws and is non-promotional.

Product information provided in these documents may differ with other published data due to the limited scope of the information published here. In case of doubt, please refer to the prescribing information approved by the FDA.

No Medical Advice Included

Patients: Nothing in these documents should be construed as the giving of medical advice or the making of a recommendation. These documents should not be relied on as the basis for any decision or action or replace medical advice, medical visits or recommendations from health care providers. Any questions regarding the information in these documents should be directed to your physician.

Healthcare Providers: This is not a prescription consultation service. The information in these documents is not prescribing information, and prescribing decisions should always refer to the specific labeling information approved by the FDA.

No Representation or Warranty, No Liability

While URL Pharma uses reasonable efforts to provide accurate information in these documents, everything in these documents is provided “AS IS”. URL Pharma does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including without limitation any implied warranties of merchantability, fitness for a particular purpose or non-infringement) with regard to any such information, its accuracy or completeness or the frequency that it is updated. URL Pharma assumes no liability or responsibility for any errors or omissions in the content of these documents and your use of this document is at your own risk. URL Pharma (including its officers, directors, employees or affiliates) shall not be liable for any damages of any kind or any claims or losses, resulting from or in connection with the creation or use of, or reliance on, this document.

Impermissible Use

These documents do not confer rights in any trademarks and service marks used in these documents, whether owned by URL Pharma or others. The results data provided in these documents are the property of URL Pharma and may not be copied, transcribed, published or otherwise used, without written permission.

Applicable Law

These terms and conditions shall be governed by and construed in accordance with the laws of the State of Pennsylvania, without regard to its choice of law principles

Generic Division

Product Catalog

Research and Development

Licensing

Clinical Trials

Sales Information and Customer Service

URL Pharma's generic segment encompasses multiple aspects of the generic value-chain including formulation development, manufacturing, and distribution. We utilize state of the art technology to maximize flexibility, profitability and quality control. URL Pharma has 288 ANDA (FDA generic) approvals across diverse therapeutic classes, and manufactures over 100 different capsule and tablet products.

Our most successful generic product has been felodipine, the generic version of AstraZeneca’s Plendil®. Due to the scientific complexities surrounding felodipine, URL Pharma remained the exclusive generic manufacturer of this product from 2004 until early 2008, well past brand patent expiration and the expiration of our 6 month FDA exclusivity period. Recently, URL Pharma became the first-to-file generic version of GSK’s Coreg CR™. We expect at least 6 months of generic exclusivity on this product too.

In May, 2008, we had 8 applications pending at the FDA which have a brand value of 2.2B per IMS in the most recent 12 month period. In addition, we have multiple other products under development. However, the size of brand markets do not reliably predict the profitability of the corresponding generic versions due to intense commodity market pricing pressures on generics with multiple generic FDA approvals.

To address this issue, URL Pharma achieves multiple ANDA filings per year and focuses exclusively on either Paragraph IV patent challenges, highly-complex formulations, or generic products that require clinical studies. This is consistent with our strategy to maintain pricing power beyond what is possible in the commodity generic marketplace.